The Czech Experience with Eculizumab in Severe Paediatric Shiga Toxin-Producing Escherichia coli-Associated Haemolytic Uremic Syndrome Patients

Klin Padiatr. 2022 Jan;234(1):48-51. doi: 10.1055/a-1288-3597. Epub 2020 Nov 9.

Authors

Patrik Konopasek¹, Jan David¹, Monika Marejkova², Nadezda Simankova¹, Karel Vondrak¹, Jakub Zieg¹

Affiliations

¹ Department of Pediatrics, Motol University Hospital, Praha, Czech Republic.
² National Reference Laboratory for E. coli and Shigellae, National Institute of Public Health, Praha, Czech Republic.

PMID: 33167045
DOI: 10.1055/a-1288-3597

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Child
Czech Republic
Escherichia coli Infections* / drug therapy
Hemolytic-Uremic Syndrome* / drug therapy
Humans
Shiga-Toxigenic Escherichia coli*

Substances

Antibodies, Monoclonal, Humanized
eculizumab